Table 2

Toxicity profile and safety summary

Toxicity grade1–2 N(%)3–4 N(%)All N(%)1–2 N(%)3–4 N(%)All N(%)1–2 N(%)3–4 N(%)All N(%)
Attributed to atezolizumab onlyAttributed to bevacizumab onlyAttributed to atezolizumab and bevacizumab
Cardiovascular
 Sinus tachycardia1 (9)0 (0) 1 (9)
 Hypertension2 (18)0 (0)2 (18)
 Stroke1 (9)0 (0)1 (9)
 Thromboembolic event0 (0)1 (9)1 (9)
Endocrine
 Hyperthyroidism1 (9)0 (0)1 (9)
 Hypothyroidism1 (9)0 (0)1 (9)
Gastrointestinal
 Anorexia1 (9)0 (0)1 (9)
 Diarrhea2 (18)0 (0)2 (18)1 (9)0 (0)1 (9)
 Nausea3 (27)0 (0)3 (27)1 (9)0 (0)1 (9)
 Vomiting1 (9)0 (0)1 (9)
 Pancreatitis1 (9)0 (0)1 (9)
 Aspartate aminotransferase increased3 (27)0 (0)3 (27)
 Alanine aminotransferase increased2 (18)0 (0)2 (18)
 Lipase increased1 (9)0 (0)1 (9)
 Alkaline phosphatase increased1 (9)0 (0)1 (9)
 Gastrointestinal fistula2 (18)0 (0)2 (18)
 Gastrointestinal bleeding0 (0)1 (9)1 (9)
General
 Fatigue4 (36)0 (0)4 (36)1 (9)0 (0) 1 (9)1 (9)0 (0) 1 (9)
 Fever3 (27)0 (0)3 (27)
 Pain1 (9)0 (0)1 (9)
Hematologic
 Neutropenia1 (9)0 (0)1 (9)
 Anemia0 (0)1 (9)1 (9)
Musculoskeletal
 Muscle weakness0 (0)1 (9)1 (9)
 Arthralgia1 (9)0 (0)1 (9)
 Back pain1 (9)0 (0)1 (9)
 Myalgia1 (9)0 (0)1 (9)
Neurologic
 Peripheral sensory neuropathy0 (0)1 (9)1 (9)
 Arachnoiditis0 (0)1 (9)1 (9)
 Sensorineural hearing loss0 (0)1 (9)1 (9)
 Headache1 (9)0 (0)1 (9)
 Depression1 (9)0 (0)1 (9)
 Encephalopathy0 (0)1 (9)1 (9)
 Meningitis0 (0)1 (9)1 (9)
Respiratory
 Cough1 (9)0 (0)1 (9)
 Pneumonitis1 (9)0 (0)1 (9)
 Dyspnea2 (18)0 (0)2 (18)